✦ LIBER ✦

Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial

✍ Scribed by Metz, L.; Li, D.; Traboulsee, A.; Myles, M.; Duquette, P.; Godin, J.; Constantin, M.; Yong, V.

Book ID: 118029835
Publisher: SAGE Publications
Year: 2009
Tongue: English
Weight: 317 KB
Volume: 15
Category: Article
ISSN: 1352-4585
DOI: 10.1177/1352458509106779

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Glatiramer acetate in primary progressiv

Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial

✍ Jerry S. Wolinsky; Ponnada A. Narayana; Paul O'Connor; Patricia K. Coyle; Corey 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 349 KB 👁 2 views

## Abstract ## Objective To determine whether glatiramer acetate (GA) slows accumulation of disability in primary progressive multiple sclerosis. ## Methods A total of 943 patients with primary progressive multiple sclerosis were randomized to GA or placebo (PBO) in this 3‐year, double‐blind tri

Intravenous immunoglobulin treatment in

Intravenous immunoglobulin treatment in relapsing-remitting multiple sclerosis: A randomized, double-blind multicenter, placebo-controlled trial

✍ A. Achiron; R. Gilad; S. Hassin; Y. Barak; U. Gabbay; I. Ziv; Y. Goldhamer; E. M 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 144 KB

Rituximab in patients with primary progr

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

✍ Kathleen Hawker; Paul O'Connor; Mark S. Freedman; Peter A. Calabresi; Jack Antel 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB 👁 2 views

## Abstract ## Objective Rituximab, a monoclonal antibody selectively depleting CD20+ B cells, has demonstrated efficacy in reducing disease activity in relapsing‐remitting multiple sclerosis (MS). We evaluated rituximab in adults with primary progressive MS (PPMS) through 96 weeks and safety thro

Neuropsychological performance during a

Neuropsychological performance during a double-blind, placebo-controlled trial of copolymer-1 in relapsing-remitting multiple sclerosis

✍ M. Grossman; K. Onishi; H. Thompson; M. D'Esposito; C. Armstrong; J. Cohen 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 156 KB

European/Canadian multicenter, double-bl

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis

✍ Giancarlo Comi; Massimo Filippi; Jerry S. Wolinsky 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 698 KB

## Abstract Two prior double‐blind, placebo‐controlled, randomized trials demonstrated that glatiramer acetate (GA) reduces relapse rates in patients with relapsing remitting multiple sclerosis (RRMS). This study was designed to determine the effect, onset, and durability of any effect of GA on dis

Randomized double-blinded placebo contro

Randomized double-blinded placebo controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24 months clinical and MRI results

✍ I. Millefiorim; C. Gasperini 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 136 KB